Sunshine Biopharma

Sunshine Biopharma Current Liabilities

The Current Liabilities of Sunshine Biopharma (SBFM) as of Oct 31, 2026 is 6.18 M USD. In the previous year, Current Liabilities was 6.25 M USD — a change of -1.26% (lower).

Current Liabilities

6.18 MUSD

YoY

-1.26%

Last updated:

Current Liabilities of Sunshine Biopharma is 2025 6.18 M USD. Current Liabilities of Sunshine Biopharma was 2024 6.25 M USD. It decreases by -1.26% lower compared to the previous year.

The Sunshine Biopharma Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.58 M USD
Jan 1, 2019
1.57 M USD
Jan 1, 2020
2.04 M USD
Jan 1, 2021
2.04 M USD
Jan 1, 2022
6.68 M USD
Jan 1, 2023
5.37 M USD
Jan 1, 2024
6.25 M USD
Jan 1, 2025
6.18 M USD
The Sunshine Biopharma Current Liabilities history
YEARCurrent LiabilitiesYoY
6.18 MUSD-1.26%
6.25 MUSD+16.45%
5.37 MUSD-19.61%
6.68 MUSD+227.62%
2.04 MUSD-0.00%
2.04 MUSD+29.85%
1.57 MUSD-0.88%
1.58 MUSD+6.83%
1.48 MUSD+185.16%
520,104.00USD-78.46%
2.41 MUSD+135.08%
1.03 MUSD+1,768.98%
54,950.00USD-57.19%
128,367.00USD+3,638.12%
3,434.00USD-69.89%
11,404.00USD-20.33%
14,314.00USD-66.71%
43,000.00USD+86.96%
23,000.00USD+1,050.00%
2,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sunshine Biopharma Stock analysis

What does Sunshine Biopharma do? Sunshine Biopharma Inc., based in Pointe-Claire, Quebec, is a biotechnology company focused on developing and commercializing oncology and antiviral drugs. The company employs 46 full-time staff and operates through two segments: generic prescription pharmaceuticals and over-the-counter products. It develops proprietary drugs such as Adva-27a for pancreatic cancer, K1.1 mRNA for liver cancer, and SBFM-PL4 for antiviral applications. The firm also manages subsidiaries NoraPharma Inc. and Sunshine Biopharma Canada Inc., which handle generic and OTC product portfolios respectively. Sunshine Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunshine Biopharma stock

Current Liabilities of Sunshine Biopharma is 6.18 M USD in 2025.

Current Liabilities of Sunshine Biopharma changed from 6.25 M USD to 6.18 M USD, representing a -1.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Sunshine Biopharma since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Sunshine Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Sunshine Biopharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sunshine Biopharma